

Table S1. Primer sequences used in this study

Primer Name	Primer sequence (5' to 3')
RTA2-5DR	AAGCCAAGGCTTCGCCTCAATTGGGCCAAGAGAATGATCCGAATTAAAT TTTATTTTATGTTGTTTTTCGTGGAATTGTGAGCGGATA
RTA2-3DR	TGTCGATGACTTTTGGTACGCACATTTTGATAATCGATAGAGACAAATATC GAAATTGGTCCTAATATTATTTCCAGTCACGACGTT
BCR1-5DR	ACTGCCAACTTTGAAATTAATATTCCCCCTGAAAATTTGTCTCCTTCAATC AAACGATCAAATTATTCTATAATACGACTCACTATAGGGC
BCR1-3DR	TTATATAACAAACGAGTAAAGTAAGAACACTATAAAAAAGAAACAACATC AAAAACATCACAAGACATAAAGCTATGACCATGATTACGCCA
BCR1OE-5'	AAAACACACACACAGTAATAAGTTTTCTCCAGTGACAACTTTTCACTTTA CTCCCCCTCCTTAATTTATAATCAAGCTTGCCTCGTCCCC
BCR1OE-3'	GATTATAAGCCATAGATGCGTGCTGTGATTGATGGGAATCGTTTTGAAGTA CTTGTGATGTCCCTGACATATTTGAATTCAATTGTGATG
MAL31OE-5'	ATATCTTGAAACTAGTCGTTGGTTATTCATATTTGTTCAACAACAAAAAGT TCTATATTTAACCGTTGAAATCAAGCTTGCCTCGTCCCC
MAL31OE-3'	CATCCAAACTCACGATGGATGGAGTCGACACATTTTTTTCATCTGATTCCG GTCTATATTCTTCAATGGTCATATTTGAATTCAATTGTGATG
RTA1OE-5'	AGCAAGTCATAAATGATGGTTAAACAGTTTTAGATAGTTTAAGGATAAGTG ATATTTACTTGAGTCATTCATCAAGCTTGCCTCGTCCCC
RTA1OE-3'	TACTTGTGGAAGTTGGCAAGGAAGTAGGTGTCCATGATGGTAGATATTGA TTTAAAAGAGAGACTCCGTCCATATTTGAATTCAATTGTGATG
SSD1OE-5'	TATTAATCTCAATTTGGTTGGATTTCATTCATTA AAAACTATCTGGTCAACAA TTCAATTTATTACAATTTGGTGAGGCAATCAAGCTTGCCTCGTCCCC
SSD1OE-3'	GCAAGTTTTTCCCCTTTCTGCTGGAAACCCTGGCTGGGGTATTATTACTGT TGTTGTTGTAATCTTGTGACGAGCTCATATTTGAATTCAATTGTGATG
ACT1RT-F	CTTCTCAATCTTCTGCCATTGA

ACT1RT-R	TTCTGGAGCTCTGAATCTTTCG
ACE2RT-F	ACTACCAGACACTGCCCAAG
ACE2RT-R	TGATGGTGGATACTGCTGGC
ADA2RT-F	CAGAGCTGCCCATATCAAA
ADA2RT-R	TGGCCATTACCATTGAAAGA
BCR1RT-F	AATGCCTGCAGGTTATTTGG
BCR1RT-R	TTTTAGGTGGTGGTGGCAAT
GSL1RT-F	ATGGCGGGTATGTTCTGG
GSL1RT-R	AGGTGCCAATACAACCTGC
HOG1RT-F	GGGACTGTTTTTCAAATCACCA
HOG1RT-R	TCTTTTTGCCAATACTGAGGTCA
MDM10RT-F	TCTTCATCATCAGCGTGTCC
MDM10RT-R	ATGCGGCTGTCACTGTCTC
PBS2RT-F	GAAAATTCACGATGCGCCA
PBS2RT-R	ATAGATGACGATGACGCCTGC
RTA1RT-F	GCTGGCGAGGGTATTTGATA
RTA1RT-R	ATTGCCACAATGGCTTTCAT
RTA2RT-F	TCAAGTTGTGGCGATGAC
RTA2RT-R	TGACGATGACCTCTTACC
SSD1RT-F	AGTTGGTACTTACGATG
SSD1RT-R	ATCTCCCAAGCCAGCATG
URA3-F	TGCTGGTTGGAATGCTTATTTG
URA3-R	TGCAAATTCTGCTACTGGAGTT
VPS51RT-F	AATCTGGACAATGCCACAAC
VPS51RT-R	AATCAAGTTGTCAATGTCGTTTAGA

Table S2. In vitro antifungal susceptibilities of selected *Candida albicans* isolates to each of five antifungal drugs

<b>Isolate</b>	<b>MIC (µg/mL)</b>				
	<b>AMB</b>	<b>FLU</b>	<b>VORI</b>	<b>MICA</b>	<b>CASP</b>
DAY185	0.5	0.25	0.03	0.03	0.06
CA024 (AMP-S)	0.125	0.25	0.03	0.03	0.03
CA080 (AMP-R)	0.25	0.25	0.03	0.03	0.125

AMB, amphotericin-B; FLU, fluconazole; VORI, voriconazole; MICA, micafungin; CASP, caspofungin